PL
 |
EN
Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl
Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 9

Liczba wyników na stronie
first rewind previous Strona / 1 next fast forward last
Wyniki wyszukiwania
Wyszukiwano:
w słowach kluczowych:  apalutamide
help Sortuj według:

help Ogranicz wyniki do:
first rewind previous Strona / 1 next fast forward last
1
Content available Apalutamide as a new option for postponing metastatic disease in hormone -resistant patients with biochemical recurrence in prostate cancer
100%
Dąbek B.
OncoReview
|
2023
|
tom 13
|
nr 1
24-26
EN
Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for cancer patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall survival times and positively impacts quality of life. This case shows how apalutamide lowered tPSA level and postponed metastatic disease.
2
Content available Apalutamide as a therapeutic option in case of local failure in the nmCRPC
80%
Stankiewicz M.
OncoReview
|
2023
|
tom 13
|
nr 1
13-19
EN
Apalutamide is a non-steroidal selective androgen receptor inhibitor approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. The paper describes a case of a patient diagnosed with prostate cancer with a long-term course of the disease. The patient was diagnosed with a non-metastatic castration-resistant stage 18 years after primary treatment. Systemic treatment with apalutamide was recommended. Initially, the treatment was carried out as part of the extended access to apalutamide program and from March 2022 as part of the B.56 drug program. The study presents the effectiveness and safety of the therapy in a 12-month follow-up period and discusses controversial aspects of the patient's previous treatments.
3
Content available Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56
80%
Trzebiński K.
OncoReview
|
2023
|
tom 13
|
nr 1
27-30
EN
The article contains a case report of patient diagnosed with castration-resistant non-metastatic prostate cancer, treated with a novel androgen receptor inhibitor – apalutamide.
4
Content available Apalutamide treatment of locally advanced prostate cancer
80%
Palasik M.
OncoReview
|
2023
|
tom 13
|
nr 1
31-32
EN
Prostate cancer is most commonly diagnosed cancer in men. The choice of treatment method depends on many factors: the patient’s age, other patient’s diseases, psychophysical status and expected survival time. Hormonotherapy plays very important role in patients with no possible radical treatment. New therapies apply in patients with castration-resistant metastatic prostate cancer. First registered drug in patients with biochemical progression without metastases is apalutamide.
5
Content available Apalutamide in the treatment of non-metastatic castration-resistant prostate cancer in an elderly patient with multiple comorbidities
80%
Liśkiewicz K.
OncoReview
|
2023
|
tom 13
|
nr 1
9-12
EN
Prostate cancer has been the most common malignant tumor in men in Poland since 2016 and is the second cause of death in this group of patients. The basic method of treatment in patients with advanced prostate cancer is androgen deprivation therapy, however, over time, the tumor evolves into a castration-resistant form, which poses a significant threat to the patient's life. This article presents a case of an elderly patient with internal diseases, who in the castration-resistant stage, was treated with a new generation androgen receptor blocker – apalutamide – in the first line of systemic treatment.
6
Content available Prostate cancer in an elderly patient with a history of comorbidities
80%
Stryczyńska-Mirocha A. , Mirocha M.
OncoReview
|
2023
|
tom 13
|
nr 1
3-5
EN
Prostate cancer is the most common cancer in men in Poland. The choice of treatment method depends on many factors, including the stage of the disease, the patient's age, life expectancy, the presence of comorbidities and the general condition of the patient. Hormone therapy is one of the basic methods of prostate cancer treatment, both in adjuvant and palliative treatment. Castration-resistant prostate cancer is an incurable disease. However, the introduction of new hormonal drugs to therapy significantly extended the survival time of patients with relatively low harmfulness of therapy.
7
Content available Apalutamide – 10 clinically important facts
60%
Juszczak K. , Drewa T.
OncoReview
|
2021
|
tom 11
|
nr 3
85-88
EN
Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over timeduring hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. Apalutamide is used in the treatment of patients with non-metastatic as well as metastatic prostate cancer. This article presents the most important clinical facts about apalutamide.
8
Content available Apalutamid for treatment of nonmetastatic castration-resistant prostate cancer - case study
60%
Sikora-Kupis B.
OncoReview
|
2023
|
tom 13
|
nr 1
6-8
EN
A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration-resistant prostate cancer who was treated with apalutamide.
9
Content available The site of apalutamide in the treatment of prostate cancer
60%
Juszczak K. , Drewa T.
OncoReview
|
2021
|
tom 11
|
nr 4
120-122
EN
Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. The article presents the role of apalutamide in the treatment of prostate cancer and its effectiveness. Moreover, attention was drawn to the need for close cooperation between the urologist and the oncologist in order to optimize the treatment of a patient with progressive prostate cancer.
first rewind previous Strona / 1 next fast forward last
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.